USB Pharma

UCB is a global biopharmaceutical company headquartered in Brussels, Belgium, specializing in the discovery and development of innovative medicines for severe diseases of the immune and central nervous systems. The company is widely recognized for its leadership in epilepsy, with a portfolio featuring blockbuster treatments like Keppra and Vimpat, as well as its immunology franchise led by the TNF-inhibitor Cimzia. UCB has recently entered a significant growth phase with the launch of Bimzelx for psoriasis and the approval of novel therapies for myasthenia gravis, including Rystiggo and Zilbrysq. Through strategic acquisitions such as Ra Pharmaceuticals and Zogenix, UCB continues to expand its footprint in rare diseases and advanced modalities like gene therapy.